The cost-effectiveness of pembrolizumab monotherapy versus platinum-based chemotherapy for patients with first-line advanced, PD-L1 positive (≥1%) NSCLC without EGFR or ALK mutation was reported in six studies based on the KEYNOTE-042 clinical trial data. Here, ALK is linked to non-small cell lung carcinoma.